Gilead Sciences, Inc. revised earnings guidance for the full year 2022. For the year, the company revised total product sales expectations between $24.5 billion and $25.0 billion, compared to $23.8 billion and $24.3 billion previously, total product sales, excluding Veklury, between $22.0 billion to $22.5 billion, compared to $21.8 billion and $22.3 billion previously and earnings per share between $2.90 and $3.30, compared to $3.00 and $3.50 previously.
Market Closed -
Other stock markets
|
After market 07:58:37 pm | |||
65.27 USD | -2.70% | 66.56 | +1.98% |
07:15am | News Highlights : Top Company News of the Day - Friday at 1 AM ET | DJ |
05:15am | News Highlights : Top Company News of the Day - Thursday at 11 PM ET | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.43% | 81.39B | |
+24.94% | 556B | |
-6.33% | 354B | |
+19.90% | 331B | |
+7.95% | 296B | |
+13.74% | 233B | |
+5.75% | 201B | |
-10.18% | 193B | |
-12.26% | 143B | |
-6.47% | 144B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Gilead Sciences, Inc. Revises Earnings Guidance for the Full Year 2022